5-MeO-DMT molecular structure. This diagram does not show a finished medicine or identify a pill.
PubChem / National Library of Medicine · Structure images reusable under PubChem citation guidelinesAbout 5-MeO-DMT
5-MeO-DMT means 5-methoxy-N,N-dimethyltryptamine. It is a separate tryptamine from N,N-DMT, not a stronger brand or interchangeable version of it.
Also searched as: 5 meo dmt · 5-methoxy-N,N-dimethyltryptamine
Buy 5-MeO-DMT: pricing & legal access
5-MeO-DMT online: availability & product information
5-MeO-DMT is federally listed in Schedule I in the United States. Research authorization is different from retail access. DrugRX has no verified consumer pharmacy price or purchasing pathway for it.
Pricing status: No live price feed or verified quote. DrugRX does not sell or dispense products.
Sources: DEA — Controlled substances alphabetical list (October 2026)
5-MeO-DMT information
Identity and clinical research
Researchers have investigated standardized 5-MeO-DMT formulations. A small placebo-controlled intranasal study in healthy participants evaluated short-term safety and drug effects, not general effectiveness for every psychiatric condition.
Side effects and safety limits
Nasal discomfort, nausea, headache and vomiting were reported in that trial. Participants were screened and monitored. Findings from a small supervised study do not establish safety for unsupervised use or unverified products.
Dosage: formulation matters
There is no self-treatment recommendation on this page. Routes and formulations differ, and clinical-study quantities cannot be transferred to products of uncertain identity or purity.
Sources: Phase 1 intranasal 5-MeO-DMT trial (2024) · Clinical pharmacology of 5-MeO-DMT (2022)
Interactions and precautions
Monoamine oxidase inhibitors can alter metabolism and increase toxicity concerns. The clinical pharmacology literature discusses this interaction; combinations with other psychoactive substances require particular caution.
Chemical identity
The 5-methoxy substitution distinguishes 5-MeO-DMT from N,N-DMT. A close structural relationship does not make the compounds interchangeable, and reports using the word DMT should identify which molecule was actually studied.
What the BPL-003 trial studied
A placebo-controlled phase 1 study enrolled 44 healthy participants to investigate a specific intranasal benzoate-salt formulation. It assessed pharmacokinetics, tolerability and changes in consciousness, rather than proving effectiveness for every psychiatric diagnosis.
Absorption and duration in research
The study found rapid absorption and elimination with the investigated formulation. The timing of a blood concentration, the duration of subjective effects and the duration of clinical observation are different measurements; none alone establishes a safe self-use schedule.
5-MeO-DMT versus 4-AcO-DMT
5-MeO-DMT has a methoxy group at one position; 4-AcO-DMT is an acetoxy-substituted tryptamine investigated in relation to psilocin metabolism. Their names describe different chemistry and evidence bases, not a strength ranking.
Sources: Clinical pharmacology of 5-MeO-DMT (2022) · Laboratory study of psilacetin metabolism (2022)
Sources and editorial notes
Prepared by DrugRX using the references linked below. Sources were consulted on 2026-10-31. This page has not been independently reviewed by a clinician. Research findings, medication approval and legal permission are separate questions.
- Phase 1 intranasal 5-MeO-DMT trial (2024)
- Clinical pharmacology of 5-MeO-DMT (2022)
- Laboratory study of psilacetin metabolism (2022)
- DEA — Controlled substances alphabetical list (October 2026)
Legal information is a dated U.S. reference. Product rules and local laws may change. Where the evidence does not establish a dose, interaction profile or price, the page states that limitation.